Patents by Inventor Ivan Leo Pinto

Ivan Leo Pinto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 9266841
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 23, 2016
    Assignee: Glaxo Group Limited
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • NOVEL COMPOUNDS
    Publication number: 20150080418
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Ivan Leo PINTO, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • NOVEL COMPOUNDS
    Publication number: 20150045375
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Deirdre Mary Bernadette HICKEY, Robert John IFE, Colin Andrew LEACH, Ivan Leo PINTO, Stephen Allan SMITH, Steven James STANWAY
  • Compounds
    Patent number: 8871775
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: October 28, 2014
    Assignee: Glaxo Group Limited
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • NOVEL COMPOUNDS
    Publication number: 20130150383
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: February 6, 2013
    Publication date: June 13, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Ivan Leo PINTO, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes
    Patent number: 8394808
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: March 12, 2013
    Assignee: Glaxosmithkline LLC
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • Compounds
    Patent number: 8268839
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: September 18, 2012
    Assignee: Glaxosmithkline LLC
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • NOVEL COMPOUNDS
    Publication number: 20120172378
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Application
    Filed: December 2, 2011
    Publication date: July 5, 2012
    Inventors: Deirdre Mary Bernadette HICKEY, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • Xanthine derivatives as selective HM74A agonists
    Patent number: 8143264
    Abstract: The present invention relates to a xanthine compound derivative which is 3-butyl-8-chloro-1-(3-{5-[(4-fluorophenyl)methyl]-2H-tetrazol-2-yl}propyl)-3,7-dihydro-1H-purine-2,6-dione: a pharmaceutically acceptable salt thereof, corresponding pharmaceutical formulations, combinations, preparation methods and methods or uses in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: March 27, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Richard Jonathan Daniel Hatley, Andrew McMurtrie Mason, Ivan Leo Pinto
  • XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
    Publication number: 20110257205
    Abstract: The present invention relates to compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: April 18, 2011
    Publication date: October 20, 2011
    Inventors: Richard Jonathan Daniel HATLEY, Andrew McMurtrie Mason, Ivan Leo Pinto
  • XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
    Publication number: 20100179128
    Abstract: The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial
    Type: Application
    Filed: August 8, 2006
    Publication date: July 15, 2010
    Inventors: Richard Jonathan Daniel Hatley, Jag Paul Heer, John Liddle, Andrew McMurtrie Mason, Ivan Leo Pinto, Shahzad Sharooq Rahman, Ian Edward David Smith
  • XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
    Publication number: 20100168122
    Abstract: The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial
    Type: Application
    Filed: August 8, 2006
    Publication date: July 1, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Richard Jonathan Daniel Hatley, Andrew McMurtrie Mason, Ivan Leo Pinto
  • NOVEL COMPOUNDS
    Publication number: 20100160354
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: March 4, 2010
    Publication date: June 24, 2010
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS
    Publication number: 20100144765
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Application
    Filed: February 18, 2010
    Publication date: June 10, 2010
    Inventors: Deidre Mary Bernadette HICKEY, Robert John IFE, Colin Andrew LEACH, Ivan Leo PINTO, Stephen Allan SMITH, Steven James STANWAY
  • Xanthines with HM74A receptor activity
    Patent number: 7713982
    Abstract: The present invention relates to a therapeutically active xanthine derivative compound of formula (I): corresponding pharmaceutical formulations containing, manufacture processes for, methods or uses of such compounds in therapy, in particular for treatment of diseases where under-activation of the HM74A receptor contributes to such diseases or where activation of the HM74A receptor will be beneficial.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: May 11, 2010
    Assignee: Smithkline Beecham Corporation
    Inventor: Ivan Leo Pinto
  • 5,6-trimethylenepyrimidin-4-one compounds
    Patent number: 7652019
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Grant
    Filed: January 6, 2009
    Date of Patent: January 26, 2010
    Assignee: SmithKline Beecham PLC
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • NOVEL COMPOUNDS
    Publication number: 20100010021
    Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: September 2, 2009
    Publication date: January 14, 2010
    Inventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
  • Pyrimidine compounds
    Patent number: 7638520
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atheroscelerosis.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: December 29, 2009
    Assignee: SmithKline Beecham, plc
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • Xanthine Derivatives with HM74A Receptor Activity
    Publication number: 20090209561
    Abstract: The present invention relates to therapeutically active xanthine compound derivatives, corresponding pharmaceutical formulations containing, processes for making or manufacture and the use of the aforementioned compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
    Type: Application
    Filed: April 1, 2005
    Publication date: August 20, 2009
    Inventors: Richard Jonathan Daniel Hatley, Ivan Leo Pinto
  • 5,6-Trimethylenepyrimidin-4-one compounds
    Publication number: 20090170877
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Application
    Filed: February 18, 2009
    Publication date: July 2, 2009
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway